17 July 2024 in The FASEB Journal
23 March 2026 in Nephrology Dialysis Transplantation
Background: Belimumab, a monoclonal antibody targeting B lymphocyte stimulator, has shown benefits in systemic lupus erythematosus and lupus nephritis, but its role in IgA nephropathy (IgAN) remains unclear. We evaluated the effectiveness and safety of belimumab in IgAN. Methods: This retrospective cohort study included biopsy-proven IgAN patients at Tongji Hospital, China (July 2020–June 2024). Sixty-nine patients treated with belimumab were compared with 137 propensity score–matched controls receiving standard therapy. The primary outcome was proteinuria remission, defined as a reduction in 24-h urinary protein excretion or urinary protein-to-creatinine ratio (UPCR) to 600 mg/g and those receiving RAAS inhibitors, belimumab demonstrated comparable or superior proteinuria reduction. No excess of common adverse events was observed in the belimumab group. Conclusion: Belimumab treatment was associated with higher proteinuria remission rates in patients with IgAN, without an increased incidence of common adverse events. These findings suggest that belimumab may represent a superior therapeutic approach for IgAN in real-world clinical practice.
1 January 2025 in Mediators of Inflammation
Objectives: Previous research has demonstrated associations between various inflammatory cytokines and IgA nephropathy (IgAN). However, the causal relationships between them remain unclear. The purpose of this study is to extensively analyze the causal links between 91 circulating cytokines and IgAN. Methods: This study commenced with a two‐sample bidirectional Mendelian randomization analysis. Genetic variations associated with 91 circulating inflammatory cytokines were extracted from genome‐wide association study (GWAS) data involving individuals of European ancestry ( n = 14824). In the corresponding GWAS dataset, the genetic variations for IgAN were obtained from a Finnish cohort of European ancestry, consisting of a case group ( n = 653) and a control group ( n = 411528). The findings from the Mendelian randomization analysis were subsequently subjected to preliminary validation using the GSE116626 dataset from the GEO database. Results: Our MR analysis indicates that transforming growth factor‐alpha (TGF‐alpha), leukemia inhibitory factor (LIF), and C–C motif chemokine 19 (CCL19) are linked to an increased risk of IgAN. There were no causal connections found when IgAN was used as an exposure and the 91 circulating inflammatory cytokines as outcomes. In addition, the GSE116626 dataset from the GEO database revealed significant upregulation of CCL19 in renal tissues from patients diagnosed with IgAN. Conclusions: This study shows a causal link between inflammatory cytokines and IgAN, suggesting that TGF‐alpha, LIF, and CCL19 may act as upstream mediators in the pathogenic pathways of IgAN. The critical role of CCL19 in the pathogenesis of IgAN was further validated using data from the GEO database. However, whether these cytokines can be used to predict or ameliorate the progression of IgAN requires further investigation.